Morgan Stanley Turns Bullish on Lemonade — Tesla Partnership Sparks $85 Price Target
Morgan Stanley upgrades Lemonade to Overweight with $85 PT on Tesla self-driving insurance partnership and first-mover edge.
NOTRELOAD AI
Delta Air Lines Raises Q1 Revenue Forecast to High Single Digits as Demand Surges Despite Higher Fuel Costs
Delta Air Lines raised its Q1 2026 revenue guidance to high single-digit growth after strong March demand from leisure and corporate customers. Earnings stay on track despite higher fuel costs.
Target Hospitality Upgraded to Outperform: Oppenheimer Bets Big on Data Center Housing Pivot
Oppenheimer upgrades Target Hospitality to Outperform with $11 price target, citing strong data center workforce housing pivot amid AI boom and recent expansions.
LENSAR-Alcon Merger Terminated After FTC Block Threat; Stock Plunges
LENSAR and Alcon have mutually terminated their merger after the Federal Trade Commission threatened to block the deal.
Rhythm Announces EMANATE Topline Results: Primary Endpoints Missed, But Next-Gen Drugs Get a Boost
Rhythm Pharmaceuticals announced that setmelanotide missed its primary endpoints in the Phase 3 EMANATE trial. Post-hoc analyses showed statistically significant BMI reductions in POMC/PCSK1 and SRC1 patients.
Why HSBC Just Turned Bearish on Eli Lilly: Price Wars and Overhyped Weight-Loss Expectations
HSBC downgraded Eli Lilly to Reduce from Hold, cutting its price target to $850 from $1,070. The analyst cites an overhyped $150B+ obesity market, rising price competition, and expected cuts in 2026.